Rejuvenate Biomed and SAS Collaborate on AI-Driven Tools for Disease-Agnostic Drug Repurposing
Friday, August 02, 2024
Rejuvenate Biomed and SAS have announced a strategic partnership to create a new, user-friendly tool for drug repurposing. This innovative tool will help researchers and scientists uncover critical insights into drugs, diseases, and biological networks by systematically exploring hidden biological patterns. It will be built on SAS® Viya®, a powerful cloud-native AI and data platform.
The new low-code tool will combine Rejuvenate Biomed’s proven AI-driven drug discovery technology with SAS’s extensive expertise in AI. It will use SAS-based analytics and algorithms to identify novel biological interactions and will feature SAS Visual Analytics for generating detailed reports. Designed for bioscience researchers with limited coding skills, the tool will also support advanced analytics for computational biology teams.
This collaboration will boost Rejuvenate Biomed’s ability to advance and expand its drug discovery platform, third-party services, and drug development pipeline.
Dr. Ann Beliën, Founder and CEO of Rejuvenate Biomed, said, “Partnering with SAS enhances our R&D capabilities. By utilizing SAS Viya, we aim to accelerate our portfolio development and strengthen our discovery platform and collaborative efforts.”
Udo Sglavo, Vice President of Applied AI and Modeling at SAS, noted, “Working with Rejuvenate Biomed places us at the forefront of AI in biomedical research. Their choice of SAS Viya to advance their drug discovery technology highlights our commitment to delivering scalable AI solutions that improve data analysis and expedite drug development.”
Source: rejuvenatebiomed.com
